Patent 7696225 was granted and assigned to OSI Pharmaceuticals on April, 2010 by the United States Patent and Trademark Office.
Amidoaryl/amidoheteroaryl substituted thiophenes, further substituted with a heteroarylmethylamino group, are useful in the treatment of cancer.